VerifiedRx

The new R&R: pharmacy technician recruitment & retention

Drs. Meghan Swarthout and Michael Alwan share their challenges around technician recruiting and retention in the current landscape for health care organizations.
 
Guest speakers:Meghan Swarthout, PharmD, MBA, BCPS, FASHPDirector, Pharmacy Patient Care Services and Population HealthJohns Hopkins Heath System
 
Michael Alwan, PharmD, MSDirector of Pharmacy Services University of Washington Medical Center
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[02:00-04:27] Setting the stage for the current pharmacy technician landscape
[04:28-06:07] How technician recruiting and retention impacts patient care and organizations
[06:08-10:25] Other strategies to address the issue
[10:26-11:38] Contrast between a career ladder and a career lattice
[11:39-15:14] Other novel approaches
[15:15-17:12] How to track success rate
[17:13-19:55] Progress seen after making changes
[19:56-21:48] How frontline staff can contribute and help improve situation
[21:49-23:03] Advice for folks struggling with the issue
 
Links | Resources:
Recruitment, Selection, and Retention of Pharmacy Personnel (ashp.org)
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed

There’s no place like Hospital at Home

Dr. Lorie Gull, Manager of Pharmacy Operations at UMass Memorial Medical Center and Dr. John Folstad, Pharmacy Operations Manager at Mayo Clinic Health System share their insights on the accelerating shift of eligible patient care out of an in-patient setting, pre and post COVID-19. They also discuss how treating acute care patients through hospital at home programs early adopters are demonstrating success.
 
Guest speakers:Lorie Gull, BSPharm, MBA, DPLAManager, Pharmacy OperationsUMass Memorial Medical Center
 
John Folstad, PharmDPharmacy Operations ManagerMayo Clinic Health System, Eau Claire
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[01:35 -2:47] What is a Hospital at Home program
[02:48-4:35] How patients are admitted to H@H programs
[04:36-5:46] How pharmacy services are incorporated in H@H
[05:47-07:15] How Mayo and UMass programs have developed
[07:16-07:52] Why are these relatively new programs
[07:53-09:22] Pharmacy specific challenges
[09:23-10:00] How payers are managing Hospital at Home patients
[10:01-10:51] Approaches to dispensing controlled substances
[10:52-11:13] Challenges that preclude admitting patients
[11:14-12:01] Position of regulatory agencies
[12:02-12:45] What should frontline pharmacists know about H@H
[12:46-15:10] Pearls for success
[15:11-16:09] The future of H@H programs
 
Links | Resources:
Hospital-level care for adult patients where they live | Hospital at Home (hahusersgroup.org)
Acute Hospital Care at Home (cms.gov)
Hospital-at-Home (ashp.org)
CMS Announces Comprehensive Strategy to Enhance Hospital Capacity Amid COVID-19 Surge | CMS
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed

Vax Romana: Peace of mind through preventing COVID-19 vaccine errors

Dr. John Schoen and Dr. Emily Diehl share the complexities and very real potential for errors of the various COVID-19 vaccines. Multiple platforms, volumes, indications, as well as the dilution and storage instructions all contribute to the risk.
 
Guest speakers:John Schoen, PharmD, BCPSSenior Clinical Manager of Drug Information Vizient
 
Emily Diehl, PharmD, BCPPSPharmacy Executive Director for CHA Vizient
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[00:53-02:22] Emily and John’s backgrounds
[02:23-07:04] What’s been happening with COVID-19 Vaccines
[07:05-14:53] The concerns right now for adults and children vaccines
[14:54-21:07] What can be done to mitigate the risks
[20:08-22:34] Go to resources when you need clarity
 
Links | Resources:
Verified Rx: What’s new with pneumococcal vaccines?
 
CDC Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
 
ISMPErrors with COVID Vaccines Lead ISMP’s of Medication Safety Concerns from 2021
Additional risk of age-related mix-ups now that our youngest patients are eligible for COVID-19 vaccines
Age-Related COVID-19 Vaccine Mix-Ups
 
FDA – EUA page for CV19 Click Here
 
ASHP – American Society of Health-System Pharmacy Click Here
 
AAFP – American Academy Family Physicians CV19 resources Click Here
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed

No diversion? Think again: Drug diversion update

Carolyn Liptak, Pharmacy Executive Director at Vizient shares her expertise on Medication diversion in today’s health care environment. Diversion is a complex and pervasive issue that challenges health systems and creates significant impacts.
 
Guest speakers:Carolyn Liptak, MBA, RPhPharmacy Executive Director Vizient
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[01:11-02:35] Why drug diversion is an important issue
[02:36-05:47] Drug diversion technology over the years
[05:48-08:11] How drug diversion software assists in the process
[08:12-10:30] Other gaps in detection
[10:31-12:06] What frontline staff should know about diversion
[12:07-13:21] DEA Drug Take Back Day
 
Links | Resources:
DEA Drug Takeback Day
HeathcareDiversion.org
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed

The managed care equation: connecting your health plan and your pharmacists

Susan Wescott, MBA, Executive Lead of Clinical Services at Alluma discusses her insights on how clinical collaboration between a health plan and ambulatory pharmacists is an effective equation for improved outcomes and savings.
 
Guest speaker:Susan Wescott, RPh, MBAExecutive Lead of Clinical Services Alluma
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[01:45 - 05:02] Why Mayo Clinic ventured into this space
[05:03 - 08:00] What about biosimilars
[08:01 -10:18] What differentiates Alluma’s approach
[10:19 -12:35] How the pandemic impacted Alluma’s patients
[12:36 -15:30] How can Frontline Pharmacy staff utilize this in their daily work?
[15:31 -17:38] Where this is moving in the future
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed

To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 2

Dr. Mandy Leonard, Senior Director of Drug Use Policy and Formulary Management at Cleveland Clinic and Steven Lucio, Senior Principal in Pharmacy Solutions at Vizient discuss their insights on the approval, role, and coverage of Aducanumab, the first drug in a new class approved for Alzheimer’s by the FDA’s accelerated approval process.
 
Guest speakers:Mandy Leonard, PharmD, BCPSSenior Director of Drug Use Policy and Formulary Management Cleveland Clinic
 
Steven Lucio, PharmD, BCPSSenior Principal in Pharmacy Solutions Vizient
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[00:47 -3:06] Other factors driving aducanumab formulary decision making
[03:07-6:35] How CMS is managing this medication
[06:36-9:04] What should patients and families know about this medication?
[09:05-12:33] What frontline pharmacists should know about this medication
 
Links | Resources:
To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 1
EMERGE and ENGAGE
American Academy of Neurology statement
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed

To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 1

Dr. Mandy Leonard, Senior Director of Drug Use Policy and Formulary Management at Cleveland Clinic and Steven Lucio, Senior Principal in Pharmacy Solutions at Vizient discuss their insights on the approval, role, and coverage of Aducanumab, the first drug in a new class approved for Alzheimer’s by the FDA’s accelerated approval process.
 
Guest speakers:Mandy Leonard, PharmD, BCPSSenior Director of Drug Use Policy and Formulary Management Cleveland Clinic
 
Steven Lucio, PharmD, BCPSSenior Principal in Pharmacy Solutions Vizient
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[01:20 -4:16] How aducanumab fits into the treatment of Alzheimer's disease
[04:17-8:29] Accelerated Approval process and Aducanumab
[08:30-14:38] Aducanumab trials and efficacy
[14:39-17:24] Aducanumab trials and safety
 
Links | Resources:
EMERGE and ENGAGE
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed

Could this be the - plase? Tenecteplase or alteplase for acute ischemic stroke, part 2

Dr. James Braun, Neurosciences Pharmacy Clinical Specialist at SSM Health St. Louis, and Dr. Kyle Hoelting, Senior Manager of Drug Information at Vizient, continue to share their insights on the use of TNK vs Alteplase for treating acute ischemic stroke. They also discuss the nuances of this therapeutic area and share recent work from an expert panel led by Vizient.
 
Guest speakers:James Braun, PharmD, BCCCPNeurosciences Pharmacy Clinical Specialist SSM Health
 
Kyle Hoelting, PharmD, BCPSSenior Manager of Drug Information Vizient
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[00:30-3:59] Medication safety risks associated with thrombolytics
[04:00-4:42] Using one drug over another
[04:43-6:48] How frontline pharmacy staff can utilize this information
[06:49-11:44] What Vizient can add to the discussion
[11:45-11:55] When report will be released
 
Links | Resources:
Tenecteplase vs alteplase in acute ischemic stroke: Vizient expert panel
Verified Rx: Evidenced based medicine Click here
Verified Rx: Show me the data! Updates on the evidence of thrombolytic use in ischemic strokes Click here
Verified Rx: Information overload: tips and tricks for staying on top of the literature, part 1 Click here
Verified Rx: Information overload: tips and tricks for staying on top of the literature, part 2 Click here
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed

Vizient Pharmacy Market Outlook Summer 2022

Dr. Carina Dolan, Editor in Chief of Vizient’s Pharmacy Market Outlook and Senior Director of Clinical Oncology and Pharmaceutical Outcomes at Vizient, shares insights on the Summer 2022 Vizient Pharmacy Market Outlook with host Gretchen Brummel. Dr. Dolan discusses the outlook’s projection, impact of inflation, and ways that frontline staff can use the report.
 
Guest speakers:Carina Dolan, PharmD, MS, BCOPSenior Director of Clinical Oncology and Pharmaceutical Outcomes Vizient
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[00:45-1:21] Final Projection for this issue
[01:22-1:57] Highlights from this issue
[01:58-2:48] How inflation currently impacts drug prices and projections
[02:49-3:34] How frontline staff can use outlook
[03:35-4:16] Unexpected trends emerging
[04:17-5:03] Key forecast issues  
[05:04-5:35] Where listeners can go for more detailed information
 
Links | Resources:
Vizient Pharmacy Market Outlook Member link: Click Here
 
Vizient Pharmacy Market Outlook highlights public version: Click Here
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed

Could this be the - plase? Tenecteplase or alteplase for acute ischemic stroke, part 1

Dr. James Braun, Neurosciences Pharmacy Clinical Specialist at SSM Health St. Louis, and Dr. Kyle Hoelting, Senior Manager of Drug Information at Vizient, share their insights on the use of tenecteplase vs alteplase for treating acute ischemic stroke. They also discuss the nuances of this therapeutic area and share recent work from an expert panel led by Vizient.
 
Guest speakers:James Braun, PharmD, BCCCPNeurosciences Pharmacy Clinical Specialist SSM Health
 
Kyle Hoelting, PharmD, BCPSSenior Manager of Drug Information Vizient
 
Moderator:Gretchen Brummel, PharmD, BCPSPharmacy Executive DirectorVizient Center for Pharmacy Practice Excellence
 
Show Notes:
[00:58-3:00] James’ background and his role in the treatment of stroke patients
[03:01-5:09] History of tenecteplase and alteplase for ischemic stroke
[05:10-6:56] Information about trials of alteplase
[06:57-8:11] Where Tenecteplase fits in discussion
[08:12-9:51] Differences with tenecteplase and alteplase to clinicians
[9:52-12:00] What studies say about potential, practical advantages of tenecteplase
[12:01-19:55] Making the switch between agents
 
Links | Resources:
Verified Rx: Evidenced based medicine Click here
Verified Rx: Show me the data! Updates on the evidence of thrombolytic use in ischemic strokes Click here
Verified Rx: Information overload: tips and tricks for staying on top of the literature, part 1 Click here
Verified Rx: Information overload: tips and tricks for staying on top of the literature, part 2 Click here
Identifying errors and safety considerations in patients undergoing thrombolysis in acute ischemic stroke Click here
EXTEND-IA TNK Click here
Australian-TNK Click here
Meta-analysis NIHSS outcomes Click here
NOR-TEST Click here
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Google Podcasts
Spotify
Stitcher
Android
RSS Feed